Biopharmaceutical start-ups brought in 19% less funding in the first quarter of 2017 as compared with the previous quarter, but venture capital investors placed big bets on a few new companies, including a $150m Series A round for Vir Biotechnology Inc. helmed by Biogen's former CEO.
But while venture capital financings declined from one quarter to another, big pharmas and others continued to tap into the...







